Richard Larson

52PUBLICATIONS
283CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene expression (incl. microarray and other genome-wide approaches)Haematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (52)

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jan 29, 2026
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Diyanath Ranasinghe, Wei-Yu Lin, Sarah E Fordham

|Dec 15, 2025
Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

Jorge E Cortes, Timothy P Hughes, Jianxiang Wang

|Aug 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.

Ethan J Harris, Diren Arda Karaoglu, Madina Sukhanova

|Jul 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross

|Feb 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Joshua F Zeidner, David A Sallman, Christian Récher

Pageof 9

Frequent Collaborators

7 joint publications

Andrew H Wei

6 joint publications

Mark R Litzow

6 joint publications

Hartmut Döhner

6 joint publications

Anand Ashwin Patel